Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.
about
Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patientsTumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectivesA novel classification of lung cancer into molecular subtypesMolecular pathways and therapeutic targets in lung cancerMass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma.Diagnostic and prognostic value of blood samples for KRAS mutation identification in lung cancer: a meta-analysis.Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLCPrognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial.Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.Mass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignancies.Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis.Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer.VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib.Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis.Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).Emerging molecular biomarkers--blood-based strategies to detect and monitor cancer.Targeting the growth factors and angiogenesis pathways: small molecules in solid tumors.Proteomic biomarkers in lung cancer.Current clinical application of genomic and proteomic profiling in non-small-cell lung cancer.Pharmacotherapy for treatment of lung cancer in the elderly.Proteomic profiling predicts drug response to novel targeted anticancer therapeutics.The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer.Writing in PROSE proteomic-based selection for second line treatment in non-small-cell lung cancer.The value of proteomics in lung cancer.Molecular signatures of lung cancer: defining new diagnostic and therapeutic paradigms.VeriStrat: a prognostic and/or predictive biomarker for advanced lung cancer patients?The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients.Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer.Serum peptide expression and treatment responses in patients with advanced non-small-cell lung cancer.
P2860
Q26866485-31DC4125-0F6A-4D9C-A6F8-D93A93A8D39AQ27014117-66130B4B-19E6-4A85-9497-A37758A0D83AQ28731874-A446FB0C-A12B-49F1-8886-EDBF012E578FQ33688872-368FF8EC-9B15-46C9-95AE-0F8C3B7E5E5FQ33778668-D2FFA622-63BD-4082-955A-E613499CDFA1Q33829668-F82D07AC-C0BE-4618-8135-12331C9DC60EQ34311186-3C508D8E-4E14-4481-B142-7B070001B42FQ34443983-4DB59BEE-CEB9-48B9-9449-006CBC579C00Q35034044-F217893C-235F-45B3-B975-E049E1D475F5Q35081379-888FE0C6-C482-4527-B9EE-8E30C680E5F0Q35238008-E8212202-5F8A-43AB-A537-2BAA44B61E68Q35824117-BA1FA935-EA83-4CC8-93B5-7FEF0D5CF372Q36089579-C1525AAA-5CB7-4120-A119-054A6134CDB9Q36419366-5AFF865F-B303-4A0A-9FF9-30C7CBB99F0EQ37334996-A38C8F4A-19C4-4904-A593-8CF4F822CFF5Q37709570-5A98B9F4-9C95-4774-AA93-B90D24902E45Q37848663-2A24826D-3BDC-4D0C-81A5-1AB4BC25D5D2Q37863629-80A6D8CD-429F-4619-8A3E-C386C89797BFQ38100750-C9EFF372-CCD1-4758-B030-3024131D71E3Q38172914-7327E155-50D2-457A-84E3-46357D98CCCDQ38386745-A0C4C821-5DF1-49D9-AF17-6BEA78E0D4BCQ38765422-8401A891-B0C0-4401-8914-F9F5AF7AF4CEQ38768030-F8CC78C4-90A4-4FA7-AE6C-25B9D501163AQ41814784-54CDC152-1651-4695-844B-D5FF32966566Q43183700-DE7F71FB-D842-4263-BB10-92C32A9A37BBQ44582343-63C37E7D-3A1A-4F42-BA45-5639360CE2BDQ51136000-B6D3165F-A569-4513-A295-569302CC46BDQ52646495-E5683A3F-D6EA-4827-8DEB-D1998821082FQ54322781-DE6440DE-FEC4-4B8A-9A25-10F1FA35D875Q54977786-5C9A5732-CEDA-40EF-B9BD-51A9E1B1DE13
P2860
Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Genetic and proteomic features ...... operative Oncology Group 3503.
@ast
Genetic and proteomic features ...... operative Oncology Group 3503.
@en
Genetic and proteomic features ...... operative Oncology Group 3503.
@nl
type
label
Genetic and proteomic features ...... operative Oncology Group 3503.
@ast
Genetic and proteomic features ...... operative Oncology Group 3503.
@en
Genetic and proteomic features ...... operative Oncology Group 3503.
@nl
prefLabel
Genetic and proteomic features ...... operative Oncology Group 3503.
@ast
Genetic and proteomic features ...... operative Oncology Group 3503.
@en
Genetic and proteomic features ...... operative Oncology Group 3503.
@nl
P2093
P2860
P1476
Genetic and proteomic features ...... operative Oncology Group 3503.
@en
P2093
Adriana Gonzalez
David P Carbone
Heinrich Roder
Joan H Schiller
Joseph M Amann
Ju-Whei Lee
Julie Brahmer
P2860
P304
P356
10.1097/JTO.0B013E3181C8CBD9
P577
2010-02-01T00:00:00Z